Order Article Reprints

Sasaki R, Fukushima M, Haraguchi M, Miuma S, Miyaaki H, Hidaka M, Eguchi S, Matsuo S, Tajima K, Matsuzaki T, et al. Response to Lenvatinib Is Associated with Optimal RelativeDose Intensity in Hepatocellular Carcinoma: Experience in Clinical Settings. Cancers. 2019; 11(11):1769. https://doi.org/10.3390/cancers11111769

Sasaki, Ryu, Masanori Fukushima, Masafumi Haraguchi, Satoshi Miuma, Hisamitsu Miyaaki, Masaaki Hidaka, Susumu Eguchi, Satoshi Matsuo, Kazuaki Tajima, Toshihisa Matsuzaki, and et al. 2019. "Response to Lenvatinib Is Associated with Optimal RelativeDose Intensity in Hepatocellular Carcinoma: Experience in Clinical Settings" Cancers 11, no. 11: 1769. https://doi.org/10.3390/cancers11111769

Sasaki, R., Fukushima, M., Haraguchi, M., Miuma, S., Miyaaki, H., Hidaka, M., Eguchi, S., Matsuo, S., Tajima, K., Matsuzaki, T., Hashimoto, S., Ooba, K., Kugiyama, Y., Yatsuhashi, H., Motoyoshi, Y., Shigeno, M., Kinoshita, N., & Nakao, K. (2019). Response to Lenvatinib Is Associated with Optimal RelativeDose Intensity in Hepatocellular Carcinoma: Experience in Clinical Settings. Cancers, 11(11), 1769. https://doi.org/10.3390/cancers11111769